COFOE MEDICAL to Acquire 60% Stake in Hefei Kangjuren Medical Device Technology for RMB 99.48 Million

Stock News11-19 18:30

COFOE MEDICAL (01187) has announced that on November 19, 2026, the company entered into an equity transfer agreement with the seller, Mr. Guo Bensheng, pursuant to which the company has agreed to acquire a total of 60% equity interest in the target company, Hefei Kangjuren Medical Device Technology Co., Ltd., from the seller using its own funds, for a total consideration of RMB 99.48 million.

Upon completion of the acquisition, the target company will be 60% owned by the company and will become a non-wholly-owned subsidiary of the company, with its financial results consolidated into the company's financial statements.

The company's existing product portfolio includes ventilators, oxygen concentrators, nebulizers, and other respiratory support products. This acquisition constitutes horizontal integration within the same industry, which will help consolidate the resources of both parties in product research and development, manufacturing, branding, and distribution channels. It will further enhance the company's oxygen concentrator product matrix, leverage synergies in production capacity and distribution channels, expand market share, strengthen competitive advantages, and further consolidate the company's market position in the respiratory health sector, aligning with the overall interests of the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment